WO1999047690A3 - Multigene vectors - Google Patents

Multigene vectors Download PDF

Info

Publication number
WO1999047690A3
WO1999047690A3 PCT/US1999/005781 US9905781W WO9947690A3 WO 1999047690 A3 WO1999047690 A3 WO 1999047690A3 US 9905781 W US9905781 W US 9905781W WO 9947690 A3 WO9947690 A3 WO 9947690A3
Authority
WO
WIPO (PCT)
Prior art keywords
genes
regulators
hyperplastic
lymphokines
inducers
Prior art date
Application number
PCT/US1999/005781
Other languages
French (fr)
Other versions
WO1999047690A2 (en
Inventor
Brian D Almond
Deborah Wilson
Sunil Chada
Louis A Zumstein
Original Assignee
Introgen Therapeutics Inc
Brian D Almond
Deborah Wilson
Sunil Chada
Louis A Zumstein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Introgen Therapeutics Inc, Brian D Almond, Deborah Wilson, Sunil Chada, Louis A Zumstein filed Critical Introgen Therapeutics Inc
Priority to AU30943/99A priority Critical patent/AU767880B2/en
Priority to CA002323112A priority patent/CA2323112A1/en
Priority to EP99912601A priority patent/EP1064392A2/en
Priority to JP2000536873A priority patent/JP2002506651A/en
Publication of WO1999047690A2 publication Critical patent/WO1999047690A2/en
Publication of WO1999047690A3 publication Critical patent/WO1999047690A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Abstract

The present invention is directed to the use of particular gene combinations in genetic therapy. Delivery of multiple genes to a target cell at the same time augments the action of one or both genes. This is particularly effective in attacking diseased cells such as those making up hyperplastic or neoplastic tissues. Classes of genes that may be used in combination are tumor suppressors, cytokines and lymphokines, toxins, inducers of apoptosis, antisense oncogenes, single-chain antibodies, ribozymes, transcription factors and regulators, cell cycle regulators and enzymes.
PCT/US1999/005781 1998-03-16 1999-03-16 Multigene vectors WO1999047690A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU30943/99A AU767880B2 (en) 1998-03-16 1999-03-16 Multigene vectors
CA002323112A CA2323112A1 (en) 1998-03-16 1999-03-16 Multigene vectors
EP99912601A EP1064392A2 (en) 1998-03-16 1999-03-16 Multigene vectors
JP2000536873A JP2002506651A (en) 1998-03-16 1999-03-16 Multi-gene vector

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7820598P 1998-03-16 1998-03-16
US60/078,205 1998-03-16

Publications (2)

Publication Number Publication Date
WO1999047690A2 WO1999047690A2 (en) 1999-09-23
WO1999047690A3 true WO1999047690A3 (en) 1999-11-18

Family

ID=22142606

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/005781 WO1999047690A2 (en) 1998-03-16 1999-03-16 Multigene vectors

Country Status (5)

Country Link
EP (1) EP1064392A2 (en)
JP (1) JP2002506651A (en)
AU (1) AU767880B2 (en)
CA (1) CA2323112A1 (en)
WO (1) WO1999047690A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036623A2 (en) * 1999-11-05 2001-05-25 Avigen, Inc. Ecdysone-inducible adeno-associated virus expression vectors
AU2001247648B2 (en) * 2000-03-24 2006-03-30 Cold Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
GB2362884A (en) * 2000-05-30 2001-12-05 Isis Innovation Extended duration of airway gene therapy
US6579522B1 (en) 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
WO2002022176A1 (en) 2000-09-15 2002-03-21 Genvec, Inc. Method of modulating neovascularization
US6656732B1 (en) 2001-05-18 2003-12-02 Isis Pharmaceuticals, Inc. Antisense inhibition of src-c expression
CA2448132A1 (en) * 2001-05-23 2002-11-28 Fornix Biosciences N.V. Vectors for enhanced expression of vegf for disease treatment
US7223740B2 (en) 2001-05-23 2007-05-29 Fornix Biosciences N.V. Vectors for enhanced expression of VEGF for atrial disease treatment
EP1262199A1 (en) * 2001-05-23 2002-12-04 Fornix Biosciences N.V. Vectors for enhanced expression of VEGF for disease treatment
US20030086903A1 (en) 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
WO2003093303A1 (en) 2002-05-06 2003-11-13 Board Of Regents, The University Of Texas System Targeting proteins to deliver therapeutic or diagnostic reagents
CN1944655B (en) * 2006-09-04 2010-05-12 王尚武 Recombinant adenovirus of target-oriented coexpressed new p53 and P53AIP1
MX2015013842A (en) * 2013-03-30 2017-01-23 Usha Biotech Ltd Methods and constructs for expressing biologically active proteins in mammalian cells.
US20170044496A1 (en) 2014-04-10 2017-02-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced Expansion of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy
WO2017068614A1 (en) * 2015-10-23 2017-04-27 徹幸 平畑 Gene therapy composition
CN108823208B (en) * 2018-06-29 2021-11-02 中国科学院过程工程研究所 Tetracycline-induced promoter, and preparation method and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016716A1 (en) * 1993-01-21 1994-08-04 Virogenetics Corporation Recombinant virus immunotherapy
WO1995010630A1 (en) * 1993-10-12 1995-04-20 Yeda Research And Development Co. Ltd. Tumor suppressor genes, proteins encoded thereby and use of said genes and proteins
WO1996001324A2 (en) * 1994-07-05 1996-01-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Novel internal ribosome entry site, vector containing same and therapeutical use thereof
WO1996033272A1 (en) * 1995-04-18 1996-10-24 KLINIKUM DER ALBERT-LUDWIGS-UNIVERSITäT FREIBURG Vectors for the transfection of eucaryotic cells, their use and target cells transfected thereby
WO1998022606A1 (en) * 1996-11-15 1998-05-28 Rhone-Poulenc Rorer S.A. Recombinant bicistron adenovirus for treating pathological conditions linked with dyslipoproteinemia

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016716A1 (en) * 1993-01-21 1994-08-04 Virogenetics Corporation Recombinant virus immunotherapy
WO1995010630A1 (en) * 1993-10-12 1995-04-20 Yeda Research And Development Co. Ltd. Tumor suppressor genes, proteins encoded thereby and use of said genes and proteins
WO1996001324A2 (en) * 1994-07-05 1996-01-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Novel internal ribosome entry site, vector containing same and therapeutical use thereof
WO1996033272A1 (en) * 1995-04-18 1996-10-24 KLINIKUM DER ALBERT-LUDWIGS-UNIVERSITäT FREIBURG Vectors for the transfection of eucaryotic cells, their use and target cells transfected thereby
WO1998022606A1 (en) * 1996-11-15 1998-05-28 Rhone-Poulenc Rorer S.A. Recombinant bicistron adenovirus for treating pathological conditions linked with dyslipoproteinemia

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HE X -S ET AL: "CONSTRUCTION OF ADENOVIRAL AND RETROVIRAL VECTORS COEXPRESSING THE GENES ENCODING THE HEPATITIS B SURFACE ANTIGEN AND B7-1 PROTEIN", GENE, vol. 175, no. 1/02, 10 October 1996 (1996-10-10), pages 121 - 125, XP002041764 *
HUBER B.E: & LAZO J.S., EDS.: "Gene therapy for neoplastic diseases", 1994, NEW YORK ACAD. SCI., NEW YORK, XP002107137 *
LANZA F. & BI S.: "Role of p53 in leukemogenesis of chronic myeloid leukemia", STEM CELLS, vol. 13, 1995, pages 445 - 452, XP002115356 *
RYAN J.J. ET AL.: "c-myc and bcl-2 modulate p53 function by altering p53 subcellular trafficking during the cell cycle", PROC. NATL. ACAD. SCI. USA, vol. 91, June 1994 (1994-06-01), pages 5878 - 5882, XP002115355 *
WANG Y.: "bcl-2 inhibits wild-type p53-triggered apoptosis but not G1 cell cycle arrest and transactivation by WAF1 and bax", CELL GROWTH DIFFER., vol. 6, September 1995 (1995-09-01), pages 1071 - 1075, XP002115357 *

Also Published As

Publication number Publication date
WO1999047690A2 (en) 1999-09-23
AU3094399A (en) 1999-10-11
CA2323112A1 (en) 1999-09-23
JP2002506651A (en) 2002-03-05
EP1064392A2 (en) 2001-01-03
AU767880B2 (en) 2003-11-27

Similar Documents

Publication Publication Date Title
WO1999047690A3 (en) Multigene vectors
WO2000061770A3 (en) Enhancement of the immune response for vaccine and gene therapy applications
WO1999022773A3 (en) Sequences for targeting metastatic cells
WO2001037721A3 (en) Magnetic nanoparticles for selective therapy
FI973467A0 (en) DNA molecules, production and use in gene therapy
ZA200108258B (en) Methods of inducing cancer cell death and tumor regression.
WO1998035028A3 (en) An oncolytic/immunogenic complementary-adenoviral vector system
WO1997003635A3 (en) P16 expression constructs and their application in cancer therapy
WO2002000904A3 (en) Recombinant constructs and their use in reducing gene expression
IL109092A0 (en) Tumor suppressor gene, protein expressed thereby, vectors containing said gene, and use of said vector and protein in cancer treatment
WO2005123141A3 (en) Combination treatment of cancer with elicitor of gene product expression and gene-product targeting agent
WO1998035554A3 (en) Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
MX9801264A (en) Control of cd44 gene expression for therapeutic use.
WO1998048027A3 (en) Materials and methods for treatment of retinal diseases
WO1998018951A8 (en) Receptor-mediated gene transfer system for targeting tumor gene therapy
AU2004269200A8 (en) Enhancing accumulation of heterologous polypeptides in plant seeds through targeted suppression of endogenous storage proteins
MXPA03003011A (en) Methods of inducing cancer cell death and tumor regression.
AU4764801A (en) Cell-specific adenovirus vectors comprising an internal ribosome entry site
AU2001280576A1 (en) Tissue-specific self-inactivating gene therapy vector
EP1020529A3 (en) Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
WO2003085087A3 (en) Modified cea nucleic acid and expression vectors
EP1070122A4 (en) Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery
WO2003008578A3 (en) Reagents and methods for identifying gene targets for treating cancer
EP0666313A3 (en) Targeting of telomerase in cancer gene therapy.
WO2003102146A3 (en) Aptamer constructs

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2323112

Country of ref document: CA

Ref country code: CA

Ref document number: 2323112

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 536873

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 30943/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999912601

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999912601

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 30943/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1999912601

Country of ref document: EP